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Background: In response to the short-term negative inotropic and chronotropic effects of β-blockers, heart failure
(HF) guidelines recommend initiating β-blockers at low dose with gradual uptitration as tolerated to doses used in
clinical trials. However, patterns and safety of β-blocker intensification in routine practice are poorly described.
Methods: We described β-blocker intensification among Kaiser Colorado enrollees with a primary discharge
diagnosis of HF between 2001–2009. We then assessed β-blocker intensification in the 30 days prior to first hospital
readmission for cases compared to the same time period following index hospitalization for non-rehospitalized
matched controls. In separate analysis of the subgroup initiated on β-blocker after index hospital discharge, we
compared adjusted rates of 30-day hospitalization following initiation of high versus low dose β-blocker.
Results: Among 3,227 patients, median age was 76 years and 37% had ejection fraction ≤40% (LVSD). During a
median follow up of 669 days, 14% were never on β-blocker, 21% were initiated on β-blocker, 43% were
discharged on β-blocker but never uptitrated, and 22% had discharge β-blocker uptitrated; 63% were readmitted
and 49% died. β-blocker intensification occurred in the 30 days preceding readmission for 39 of 1,674 (2.3%)
readmitted cases compared to 27 (1.6%) of matched controls (adjusted OR 1.36, 95% CI 0.81-2.27). Among patients
initiated on therapy, readmission over the subsequent 30 days occurred in 6 of 155 (3.9%) prescribed high dose
and 9 of 513 (1.8%) prescribed low dose β-blocker (adjusted OR 3.10, 95% CI 1.02-9.40). For the subgroup with
LVSD, findings were not significantly different.
Conclusion: While β-blockers were intensified in nearly half of patients following hospital discharge and high
starting dose was associated with increased readmission risk, the prevailing finding was that readmission events
were rarely preceded by β-blocker intensification. These data suggest that β-blocker intensification is not a major
precipitant of hospitalization, provided recommended dosing is followed.
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β-blocker therapy has emerged as a valuable treatment to
reduce mortality and long-term hospitalization in selected
patients with heart failure (HF) and left ventricular systolic
dysfunction (LVSD) [1-3]. Patients with HF and normal left
ventricular ejection fraction (LVEF) may also benefit from
β-blockers for heart rate and blood pressure control. As a* Correspondence: Larry.Allen@ucdenver.edu
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reproduction in any medium, provided the orresult, β-blockers are used to treat most patients with HF
[4]. However, initiation and uptitration of β-blocker agents
produces acute negative inotropic and chronotropic effects,
which may lower cardiac output over the short-term [5].
As a result, there are concerns that despite the long-term
benefits, β-blockers, initiation or intensification may result
in short-term adverse events.
Recognizing these potentially deleterious acute effects
of β-blocker use, randomized controlled trials involving
β-blockers for the treatment of HF with LVSD have
used algorithms where study drug was initiated at a lowd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Consequently, guidelines recommend, “that β-blockade be
initiated at low doses and uptitrated gradually, typically at
2-week intervals in patients with reduced LVEF, and 3–
10 day intervals in patients with reduced LVEF following
newly diagnosed myocardial infarction.” [2] Existing data
suggests that initiation may occur in the ambulatory set-
ting or in the hospital setting [7]. In the controlled envir-
onment of a randomized trial, the magnitude of benefit in
the first few months of therapy appears to be similar to
that seen over the long term [8].
The patterns of initiation and uptitration of β-blockers
outside of the carefully monitored confines of randomized
controlled trials are poorly characterized. Existing observa-
tional data are frequently confined to the inpatient setting
or cross-sectional assessments in the outpatient setting.
Therefore, concerns remain about the risks of β-blocker
use in HF patients with greater comorbidity, particularly
without closely-supervised intensification. The limited data
that are available show that doses of β-blockers used in
clinical practice are on average significantly below doses
achieved in randomized controlled trials, which may reflect
residual concern about the safety of intensification [9].
To address these gaps in knowledge about the patterns
and safety of β-blocker intensification in the real world set-
ting, we evaluated a large cohort of patients with HF cared
for in community practice. The goal was to characterize
how β-blockers are initiated and uptitrated in patients with
HF during routine care and to investigate the association
between β-blocker intensification and short-term.Methods
Study setting
All patients in the study cohort were enrolled in Kaiser
Permanente Colorado (KPCO), an integrated, nonprofit,
managed care organization that provides medical services
(inpatient, outpatient, pharmacy) to more than 500,000
persons in the Denver-Boulder metropolitan area through
20 medical offices and several contract hospitals. The study
cohort included patients with a primary hospital discharge
diagnosis for HF (i.e. index HF hospitalization) between
January 1, 2001 and July 31, 2009. HF hospitalizations were
identified using the principal discharge diagnosis, defined
by International Statistical Classification of Diseases and
Related Health Problems, 9th edition (ICD-9) codes of 428.
xx, 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11,
404.13, 404.91, 404.93 or a Diagnosis Related Group of 127
(prior to October 2007) and 291, 292, or 293 (October
2007 and beyond), as previously described [10]. Prior lit-
erature suggests that a principal discharge diagnosis of HF
has a high positive predictive value compared with chart
review [11,12]. Following the index HF hospitalization,
patients were followed for subsequent events. The studywas approved by the Kaiser Permanente Institute for
Health Research Institutional Review Board.
Among 4,312 patients identified as having an index
hospitalization with a principal discharge diagnosis of HF,
we excluded those who did not have a pharmacy benefit
through KPCO (n=10) and those did not survive to hos-
pital discharge (n= 340). In order to allow for a fixed
short-term window of exposure time, we excluded those
patients who did not have at least 30 days of follow up
from the time of index hospital discharge (n=54) or had
readmission in the 30 days after index hospital discharge
(n=681). The resulting cohort included 3,227 patients.
Exposure to β-blockers
Use of β-blockers was defined as receipt of any of the fol-
lowing oral agents: acebutolol, atenolol, bisoprolol, carvedi-
lol, labetalol, metoprolol succinate, metoprolol tartrate,
nadolol, pindolol, propranolol, sotalol, and timolol. These
agents represented the available oral β-blockers within the
participating health plan and were confirmed based on a
search of pharmacy databases for all generic and brand
name formulations, including both individual and combin-
ation therapies, supplemented by National Drug Codes
and American Hospital Formulary Service codes. Of
note, there were no formulary restrictions for use of these
β-blockers at KPCO during the study period. We used
automated pharmacy data on filled outpatient prescriptions
to determine the dose and timing, and estimate the dur-
ation of receipt of β-blockers based on the days supplied
per prescription and refill patterns using a previously
established approach [11-13]. The KPCO pharmacy benefit
offered prescriptions for a nominal co-payment (typically
$5 for a month supply) and prescriptions were conveni-
ently filled at the site of clinical encounters or mailed dir-
ectly to patients, thus providing a strong incentive to fill
prescriptions within the KPCO system. Simultaneous use
of multiple β-blockers in the setting of HF is generally not
clinically indicated. Therefore, if a patient filled a prescrip-
tion for a different dose of β-blocker or an entirely different
β-blocker drug, the patient was considered to have discon-
tinued the previous β-blocker prescription as of the fill date
for the new prescription.
Data collection
Baseline patient demographics, comorbidities, vital signs
and laboratory data were derived from automated KPCO
databases. Comorbidities were defined using ICD-9 codes
within the automated databases. Data on LVEF was ascer-
tained through manual abstraction of the medical record.
The value obtained closest to the index hospitalization was
used. LVSD was defined as quantitative LVEF≤ 40% or
qualitative LVEF “moderately” or “severely” reduced. Other
HF medications including angiotensin-converting enzyme-
inhibitors, angiotensin receptor blockers, and aldosterone
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records using methods similar to those employed for
β-blocker exposure. Mortality was ascertained from
KPCO databases and validated by comparison with death
certificates registered with the State of Colorado. Follow-
up and vital status information was available through July
2009. All-cause readmissions were identified from KPCO
claims databases.
Study design
Because β-blocker intensification can occur multiple times
for a given subject and at variable times in a subject’s
clinical course, a matched case–control analysis [14] was
used to assess the association between intensification of
β-blocker dose and readmission in the subsequent
30 days. The window of 30-days was chosen based on
the known short-term negative chronotropic and ino-
tropic effects of β-blockers in combination with longer-
term outcomes data that show neutral 60-day effects
and long-term benefit [2,7]. Cases were defined by the
first occurrence of hospitalization during follow up (i.e.
a readmission event). For each case, a control patient
was randomly selected among those who had not been
admitted to the hospital up to the same amount of time
following the index hospital discharge. To increase the
number of matched case–control post-discharge time
periods, controls could subsequently become cases if they
were rehospitalized at a time point further from the index
hospitalization than the period for which they acted as a
control, provided that an appropriate matched control
could be identified. Conversely, cases were not eligible to
serve as a control for any time period occurring after their
readmission event. In addition to matching the time period
from index hospital discharge, control patients were
matched with case patients on the basis of the following
criteria: age (within 5 years), sex, year of index
hospitalization, and presence or absence of LVSD. Cases
for which a control could not be identified were excluded
from analysis. The exposure was defined as β-blocker initi-
ation or increased β-blocker dose by prescription fill in the
30 days prior to readmission for cases or the 30 days prior
to the matched time point for controls.
In contrast to the process of serial intensification of
β-blocker doses, initiation of β-blockers is a one-time
event. Therefore, we employed a separate cohort design
among the subgroup of patients not on a β-blocker during
the hospital admission who were subsequently initiated on
one. Using this approach we assessed the rate of readmis-
sion in the 30 days following β-blocker initiation, compar-
ing high- and low-dose β-blocker. High starting dose was
defined above the median initiation dose, and low dose as
at or below the median. We then evaluated the association
of antecedent high-dose versus low-dose β-blocker initi-
ation on rates of readmission in the subsequent 30 days.In addition to matched variables, the following additional
covariates were candidates for adjusted analyses based
on clinical significance: diabetes, history of myocardial
infarction, history of atrial fibrillation, history of chronic
obstructive pulmonary disease, history of chronic liver
disease, and systolic blood pressure, heart rate and cre-
atinine clearance preceding readmission for cases or
control time period for controls.
Statistical analysis
Baseline characteristics and medication use were described
at the time of index hospitalization using proportions for
categorical variables and means with standard deviations
(SD) for normally distributed continuous variables and
medians and interquartile ranges (IQR) or total range for
non-normal data.
We used multivariable logistic regression to evaluate
the association of 1) hospital readmission with antecedent
β-blocker intensification in the prior 30-days and 2) high-
dose versus low-dose β-blocker initiation with readmission
in the subsequent 30 days. Matching variables were
required for inclusion in the case–control analysis. Missing
data were <1% for adjustment variables: missing heart rate
n=9, blood pressure n= 9, serum creatinine n= 25. Miss-
ing covariates were imputed to the median.
SAS version 9.1 was used for all analyses (SAS Institute
Inc., Cary, NC). Statistical significance was determined at
the 2-sided alpha=0.05.
Results
Cohort characteristics and overall events
The cohort consisted of 3,227 patients, of whom 37.0%
(n=1,108) had LVSD. The median age of the cohort was
76 years, and 53.2% (n=1,715) were women (Table 1). The
median length of follow-up was 669 days. During follow-
up, 62.7% (n=2,024) patients experienced a hospital re-
admission for any cause. The median time from index
hospital discharge to first readmission was 231 days (range
31–2,814). Almost half (48.7%, or 1,572 patients) died in
follow-up.
Characterization of β-blocker use and intensification
During follow up, 14.2% (n=458) were never on a
β-blocker, 21.0% (n= 676) were not on a β-blocker during
hospitalization but subsequently started one at discharge
or during follow up, 43.0% (n= 1,388) were discharged on
a β-blocker but never had the dose increased [of which
1,054 filled this stable β-blocker prescription dose through-
out follow up and 334 stopped β-blocker during follow
up], and 21.9% (n=705) had their discharge β-blocker dose
increased during follow up. β-blocker type was divided pri-
marily among atenolol, carvedilol, metoprolol succinate,
and metoprolol tartrate (Table 1). There was a change from
Table 1 Baseline characteristics of the cohort, divided by cases and controls, for the primary case–control analysis
Characteristic OVERALL CASE Rehospitalized CONTROL Not rehospitalized
during same time interval from
index hospital discharge
N=3227 N=1674 N=1674
β-Blocker Intensification in Prior 30-Days 39 (2.3%) 27 (1.6%)
Matching variables
Age, years, median (IQR) 76.1 (67.2-83.5) 75.8 (68.6-82.9) 75.8 (68.5-82.9)
Female Gender 1715 (53.2%) 895 (53.5%) 895 (53.5%)
Year of Index Hospitalization
2001 409 (12.7%) 229 (13.7%) 229 (13.7%)
2002 393 (12.2%) 220 (13.1%) 220 (13.1%)
2003 362 (11.2%) 222 (13.3%) 222 (13.3%)
2004 401 (12.4%) 247 (14.8%) 247 (14.8%)
2005 438 (13.6%) 261 (15.6%) 261 (15.6%)
2006 354 (11.0%) 186 (11.1%) 186 (11.1%)
2007 358 (11.1%) 176 (10.5%) 176 (10.5%)
2008 344 (10.7%) 123 (7.3%) 123 (7.3%)
2009 168 (5.2%) 10 (0.6%) 10 (0.6%)
LVSD at index hosp 1108 (37.0%) 574 (34.3%) 574 (34.3%)
Covariates
History of Myocardial Infarction 427 (13.2%) 245 (14.6%) 182 (10.9%)
History of Atrial Fibrillation 1422 (44.1%) 759 (45.3%) 748 (44.7%)
History of Diabetes 1457 (45.1%) 836 (49.9%) 732 (43.7%)
History of COPD 1230 (38.1%) 707 (42.2%) 614 (36.7%)
History of Chronic Liver Disease 67 (2.1%) 33 (2.0%) 25 (1.5%)
Systolic BP preceding readmission or matched time
period, mmHg, median (IQR)
122 (110–139) 122 (110–138) 124 (110–140)
Diastolic BP preceding readmission or matched time
period, mmHg, median (IQR)
68 (60–78) 68 (60–78) 70 (60–78)
Heart rate preceding readmission or matched
control time period, bpm, median (IQR)
54 (42–68) 53 (42–67) 55 (44–66)
CrCl preceding readmission or matched control time period,
mL/min/1.73 m2, median (IQR)
50.2 (34.9-65.6) 49.8 (34.3-65.1) 55.2 (41.0-71.2)
β-Blocker Use (at anytime in follow up)
Atenolol 551 (17.1%) 307 (18.3%) 334 (20.0%)
Carvedilol 222 (6.9%) 113 (6.8%) 104 (6.2%)
Metoprolol Succinate 526 (16.3%) 266 (15.9%) 261 (15.6%)
Metoprolol Tartrate 1079 (33.4%) 634 (37.9%) 606 (36.2%)
Other β-Blocker 57 (1.8%) 31 (1.9%) 38 (2.3%)
No β-Blocker 792 (24.54%) 322 (19.2%) 331 (19.8%)
Switch β-Blocker Type During Follow Up 538 (2.1%) 343 (25.4%) 311 (23.2%)
*869 controls subsequently became cases due to hospital readmission at a time further from the index hospitalization, and thus are represented in both columns;
748 patients in the “all cohort” did not qualify as a case or a control.
SD = standard deviation; LVSD= left ventricular systolic dysfunction (LVEF<=40% or moderate/severe LV systolic dysfunction); LVEF = left ventricular ejection
fraction; COPD= chronic obstructive pulmonary disease; BP = blood pressure; mmHg=millimeters mercury; CrCl = creatinine clearance; mL=milliliter; min =minute;
m=meter.
All cells have complete data for the entire cohort, except for blood pressure and heart rate (n = 3,218), and serum creatinine (n = 3,202).
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(n=538) of patients.
Among patients initiated on β-blocker following index
hospitalization, the median time from discharge to initi-
ation was 12 days (IQR 1–100) overall, and 7 days and
41 days by LVSD and non-LVSD subgroups, respectively.
Among patients discharged on β-blocker whose dose was
increased in follow-up, the median time from discharge to
first dose escalation was 184 days (IQR 67–532) overall,
and 113 days and 266 days by LVSD and non-LVSD sub-
groups, respectively.
The β-blocker dose achieved at any point in follow up
for patients ever treated was a median of 50 mg per 24
hours for atenolol (IQR 25–50 mg), 9.375 mg per 24 hours
for carvedilol (IQR 6.25-25 mg), 50 mg per 24 hours for
metoprolol succinate (IQR 25–50 mg), and 50 mg per 24
hours for metoprolol tartrate (IQR 25–50 mg).
Among the subgroup with LVSD rates of β-blocker
use and uptitration were modestly higher: 9.2% (n=102)
were never on a β-blocker, 32.8% (n= 363) were not on
a β-blocker during the index hospitalization but subse-
quently started one, 31.6% (n=350) were discharged on
a β-blocker but never had the dose increased, and 26.4%
(n=293) had their discharge β-blocker dose increased
during follow up (p< 0.001 for comparison to patients
without LVSD).
Relationship of β-blocker intensification to readmission in
case–control analysis
Among 2,024 all-cause first readmissions, 1,674 readmit-
ted cases were matched with 1,674 controls. β-blocker in-
tensification was not significantly more common in the
30 days before readmission for cases (2.33%, n=39) in
comparison to a similar time interval for matched controls
(1.61%, n= 27; unadjusted odd ratio [OR] 1.44, 95% confi-
dence interval [CI] 0.88-2.36, p= 0.142). After adjustment
for history of myocardial infarction, diabetes, atrial fibrilla-
tion, chronic obstructive pulmonary disease, chronic liver
disease, systolic blood pressure, heart rate, and estimated
creatinine clearance at readmission, the association be-
tween intensification and readmission remained insignifi-
cant (adjusted OR 1.36, 95% CI 0.81-2.27, p= 0.246).
In similar analysis restricted to patients with LVSD
(Table 2), β-blocker initiation or uptitration occurred inTable 2 Absolute and exposure rates to β-blocker intensificat
adjusted odds ratios for exposure
Proportion with β-blocker intensification in precedi
CASE (n= 1674) CONTROL (n = 1
Total 2.33% (n = 39) 1.61% (n = 27)
LVSD 2.44% (n = 14) 2.26% (n = 13)
No LVSD 2.27% (n = 25) 1.27% (n = 14)
LVSD = left ventricular systolic dysfunction (LVEF ≤40% or moderate/severe LV systo
Cases are rehospitalized; controls are not rehospitalized during same time interval f2.44% (n=14) of cases in the 30 days before readmission
versus 2.26% (n= 13) of non-hospitalized controls during
the same post-discharge time interval (adjusted OR 1.13,
95% CI 0.50-2.54, p= 0.77). Conversely, in patients without
LVSD, β-blocker initiation or uptitration occurred in 2.27%
(n=25) of cases in the 30 days before hospitalization versus
1.27% (n= 14) non-hospitalized controls (adjusted OR was
1.54, 95% CI 0.78-3.04, p= 0.211).
Comparison of high- versus low-dose β-blocker initiation
The starting β-blocker type and dose for the 676 patients
discharged from the index hospitalization without a pre-
scription for β-blocker who subsequently initiated therapy
with a β-blocker are shown in Table 3. The 8 patients
started on labetalol, propranolol, or sotalol were excluded
from further analysis. Hospitalization within the 30 days
following outpatient initiation of β-blocker occurred in 15
of the 668 patients, 6 of 155 patients (3.87%) initiated on
high-dose β-blocker (above the median) and 9 of 513
patients (1.75%) of patients initiated on low-dose β-blocker
(median dose or lower). In a multivariable logistic regres-
sion model designed to control for other patient-level fac-
tors, patients initiated on high-dose β-blocker were more
likely to experience readmission in the subsequent 30 days
than were those patients initiated on low-dose β-blocker
(adjusted OR 3.10, 95% CI 1.02-9.40, p= 0.046). In a sensi-
tivity analysis switching the median dose from the low to
the high dose definition, this association between high
starting dose and subsequent readmission was partially
attenuated such that finding was no longer significant.
Discussion
β-blocker intensification (initiation or uptitration) occurred
in approximately half of patients following index hospital
discharge for HF. Using an adjusted matched case–control
analysis to better accommodate the short-time window be-
tween exposure to β-blocker intensification and readmis-
sion, we found no significant increase in exposure to
intensified β-blocker dose in the 30 days preceding hospital
readmission; although, the low rates of intensification lim-
ited the ability to detect even moderate relative differences
in readmission rates. In a separate analysis of the subgroup
of patients initiated on β-blocker in the ambulatory setting,
we found an association of borderline significance betweenion for case and control 30- day time periods, with










rom index hospital discharge.
Table 3 Type and dose of outpatient initiation of β-blockers, stratified by LVEF
β-Blocker Initiated LVSD (n = 362) No LVSD (n= 283)
N Dose, mg/24 hr Median (IQR) N Dose, mg/24 hr Median (IQR)
Atenolol 12 25 (12.5-25) 56 25 (25–25)
Carvedilol 63 12.5 (6.25-25) 12 9.375 (6.25-18.75)
Metoprolol Succinate 124 25 (12.5-37.5) 42 12.5 (12.5-25)
Metoprolol Tartrate 163 50 (25–50) 173 50 (25–50)
Hospitalization in next 30 days following
β-blocker initiation (unadjusted)
6 (0.93%) 9 (1.40%)
LVSD = left ventricular systolic dysfunction (LVEF ≤40% or moderate/severe LV systolic dysfunction). The 6 patients initiated on a β-blocker other than those listed
were excluded.
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readmission events. Although the original rationale for the
analysis was to test these associations, an equally important
finding that emerged from the results was the low absolute
rate of β-blocker intensification preceding readmission
events (<3% in the prior 30 days) despite initiation and
uptitration occurring in nearly half of patients at some
point in follow up. This provides objective data that the
short-term negative inotropic and chronotropic effects of
β-blockers are unlikely to play a major role in the high re-
admission rates among patients with a history of HF
hospitalization.
These data from contemporary clinical practice comple-
ment trials data. Randomized controlled trials have gener-
ally shown long-term decreases in hospitalization following
the use of β-blockers in patients with HF and LVSD, effects
which appear relatively early and continue over time [8].
Additionally, initiation of β-blockers during hospitalization
for worsening HF in a controlled trial (IMPACT-HF) was
not associated with increased readmission at 60 days [7].
The highly controlled, closely monitored setting of rando-
mized trials among a select patient population may favor
the beneficial effects of β-blockers while minimizing the
potential adverse events. The ratio of benefit to risk in
trials may be further optimized with rigid algorithms guid-
ing β-blocker intensification. The applicability of trials to
the general care setting is always a concern, especially if
many of these safety measures are not routinely employed.
Our data show relatively high starting doses for β-blockers
and that higher doses were associated with a statistically
significant but small absolute increase in readmission.
These data thus support guideline recommendations to
start β-blocker at low doses and uptitrate gradually.
Heart failure hospitalization and readmission are receiv-
ing increasing attention. However, the precipitants of heart
failure hospitalizations remain unknown. While various
interventions have been proposed to reduce readmission,
specific targets for improvement remain elusive. The find-
ings here are relevant to clinical practice and quality im-
provement initiatives as the low absolute attributable risk
of β-blocker intensification for short-term readmissionsuggests that interventions to improve rates of β-blocker
intensification among the LVSD population appear rela-
tively safe. provided guideline recommended dosing is
followed.
The overall utilization of β-blockers among patients with
LVSD who would be expected to have a guideline indica-
tion for β-blocker therapy was 91%. The observed 9% rate
of nonuse included nonadherence, as utilization data were
derived from pharmacy fills rather than prescriptions. We
were unable to perform a more detailed assessment of con-
traindications to β-blocker use, which might explain a por-
tion of β-blocker non-use. Despite this high overall
utilization rate in patients with LVSD, a more detailed as-
sessment of intensification timing and dose maximization
of β-blockers suggests potential areas for improvement.
The median time from index hospital discharge to dose
uptitration was nearly 4 months in patients with LVSD, far
longer than is recommended by clinical practice guidelines.
Furthermore, the maximum β-blocker doses achieved in
this cohort was about half that seen in randomized trials.
The reasons for these patterns are unclear. Clinicians may
be reluctant to uptitrate β-blocker dose soon after
hospitalization for HF decompensation, particularly in a
patient population with relatively high levels of comorbid-
ity. However, such reluctance was not seen in the median
time to β-blocker initiation (1 week in patients with LVSD),
making such an explanation less likely. An alternative ex-
planation is that clinicians are responding to current qual-
ity measures which tend to assess whether patients with an
indication for a therapy receive it or not, but at present do
not typically capture performance on dose maximization.
Limitations
Certain issues should be considered in the interpretation of
this study. First, the retrospective cohort design precluded
an assessment of clinical decisions around β-blocker. How-
ever, worsening symptoms should generally prompt clini-
cians to avoid rapid intensification of β-blockers, such that
the direction of bias should be towards greater readmission
in patients with less aggressive intensification. Because we
found the opposite association, this should alleviate some
Allen et al. BMC Cardiovascular Disorders 2012, 12:43 Page 7 of 8
http://www.biomedcentral.com/1471-2261/12/43concern for residual treatment selection bias. Second,
KPCO is an integrated health organization, and the find-
ings here may not be representative of the fee-for-service
setting. Third, we were not able to characterized New York
Heart Association functional classification, although we
were able to adjust for LVEF and other clinical correlates
of HF severity, including blood pressure, heart rate, kidney
function, and ischemic heart disease, which are strongly
associated with adverse outcomes in HF and rarely avail-
able in administrative datasets. Fourth, intensification of β-
blockers was determined using pharmacy dispensing that
may not capture β-blocker intensification (e.g. doubling the
dose) that occurred prior to a change in dispensing. Fortu-
nately, such undocumented practices are discouraged in
Kaiser’s integrated electronic health records. Fifth, much of
the current attention to HF hospitalization has focused on
30-day readmission rates. Because of the need to create a
30-day window to assess pre-hospitalization exposure to
β-blockers and because we found that multiple changes
to therapies were occurring immediately following index
hospital discharge, we had to exclude patients with re-
admission in these first 30 days. Sixth, our primary analysis
looked at all patients with HF, whereas β-blockers have a
HF indication only in HF patients with LVSD. However,
the majority of patients with HF and preserved ejection
fraction are prescribed β-blockers for a variety of reasons,
and questions around short-term safety may apply to
patients with a wide range of left ventricular ejection frac-
tion. Finally, the study was underpowered to detect small
relative differences, and our study is not adequately pow-
ered to look carefully at differences by important HF sub-
groups (e.g. LVSD). However, this low power was due in
part to a lower than expected intensification rate in the
30 days prior to readmission, which itself became one of
the prevailing findings from the data.
Conclusions
Although β-blocker intensification occurred in nearly half
of HF patients following index hospital discharge, readmis-
sion events were rarely preceded by β-blocker intensifica-
tion in the previous 30 days. Higher starting doses may be
associated with a relative increase in short-term readmis-
sion rates, but the low absolute attributable risk argues that
β-blocker intensification patterns are unlikely to be a major
contributor to heart failure hospitalization events. There-
fore, concern for precipitating hospitalization should
not be a major barrier to initiation and intensification
of β-blockers for the vast majority of patients with
heart failure, particularly if guideline recommendations
for β-blocker initiation and intensification are followed.
Abbreviations
CI: Confidence interval; HF: Heart failure; ICD-9: International statistical
classification of diseases and related health problems, 9th edition; IMPACT-
HF: Initiation management predischarge: process for assessment of carvediloltherapy in heart failure trial; IQR: Interquartile range; KPCO: Kaiser
Permanente Colorado health system; LVEF: Left ventricular ejection fraction;
LVSD: Left ventricular systolic dysfunction; OR: Odds ratio.
Competing interests
Dr. Allen has served as a consultant for Amgen, Janssen Scientific Affairs, and
the Robert Wood Johnson Foundation. Dr. Peterson is supported by
American Heart Association Pharmaceutical Roundtable grant 067001 N.
Dr. Masoudi reported having contracts with the Oklahoma Foundation for
Medical Quality and the American College of Cardiology Foundation and
serving on an advisory board for Amgen. No other authors reported
disclosures or competing interests.
Acknowledgements
The study was funded by unrestricted grants from Kaiser Permanente
Colorado and Amgen. Dr. Allen is currently supported by grant
1K23HL105896-01A1 from National Heart, Lung and Blood Institute. None of
the funders had any role in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; or preparation, review,
or approval of the manuscript.
Author details
1Division of Cardiology, University of Colorado Anschutz Medical Campus,
Aurora, CO, USA. 2Institute for Health Research, Kaiser Permanente Colorado,
Denver, CO, USA. 3Division of Cardiology, Denver Health Medical Center,
Denver, CO, USA. 4Division of Cardiology, University of Colorado Anschutz
Medical Campus, Aurora, CO, USA.
Authors’ contributions
Dr. LA contributed to the design of the analysis, interpretation of the data,
and drafting of the manuscript. Dr. DM contributed to the conception of the
database, modifications to the analysis, and critical revision of the
manuscript. Dr. CZ contributed by performing the majority of the analysis
and through critical revision of the manuscript. Dr. PP contributed to the
development of the database, modifications to the analysis, and critical
revision of the manuscript. Mrs. CC contributed to creation and modification
of the database, modifications to the analysis, and critical revision of the
manuscript. Ms. SS contributed to creation and maintenance of the
database, modifications to the analysis, and critical revision of the
manuscript. Mr. DB contributed to patient privacy and protection issues,
management of the database, modifications to the analysis, and critical
revision of the manuscript. Dr. DM contributed to the conception of the
database, modifications to the analysis, and critical revision of the
manuscript. Dr. FM contributed to the conception of the database,
modifications to the analysis, and critical revision of the manuscript. All
authors have critically reviewed this version of the manuscript and give final
approval of the version to be published.
Received: 27 October 2011 Accepted: 18 June 2012
Published: 18 June 2012
References
1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG,
Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA,
Stevenson LW, Yancy CW: Focused Update Incorporated Into the ACC/
AHA 2005 Guidelines for the Diagnosis and Management of Heart
Failure in Adults. A Report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice
Guidelines. Circulation 2009, 114:e391–e479.
2. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM,
Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang
WH, Teerlink JR, Walsh MN: HFSA 2010 Comprehensive Heart Failure
Practice Guideline. J Card Fail 2010, 16:e1–e194.
3. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-
Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A,
Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De
Caterina R, Dean V, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor
K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL: ESC
Guidelines for the diagnosis and treatment of acute and chronic heart
failure 2008: the Task Force for the Diagnosis and Treatment of Acute
and Chronic Heart Failure 2008 of the European Society of Cardiology.
Allen et al. BMC Cardiovascular Disorders 2012, 12:43 Page 8 of 8
http://www.biomedcentral.com/1471-2261/12/43Developed in collaboration with the Heart Failure Association of the ESC
(HFA) and endorsed by the European Society of Intensive Care Medicine
(ESICM). Eur Heart J 2008, 29:2388–2442.
4. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW: Temporal
trends in clinical characteristics, treatments, and outcomes for heart
failure hospitalizations, 2002 to 2004: findings from Acute
Decompensated Heart Failure National Registry (ADHERE). Am Heart J
2007, 153:1021–1028.
5. Mann DL: “Pathophysiology of Heart Failure. “Braunwald’s Heart disease.
In A Textbook of Cardiovascular Medicine, Volume 2. Edited by Bonow RO,
Mann DL, Zipes DP, Libby P. Philadelphia: Saunders; 2011:487.
6. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP: Clinical effects
of beta-adrenergic blockade in chronic heart failure: a meta-analysis of
double-blind, placebo-controlled, randomized trials. Circulation 1998,
98:1184–1191.
7. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M:
Predischarge initiation of carvedilol in patients hospitalized for
decompensated heart failure: results of the Initiation Management
Predischarge: Process for Assessment of Carvedilol Therapy in Heart
Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004, 43:1534–1541.
8. Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, Katus HA,
Fowler MB, Packer M: Effects of initiating carvedilol in patients with
severe chronic heart failure: results from the COPERNICUS Study. JAMA
2003, 289:712–718.
9. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M,
Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB: Dosing of beta-
blocker therapy before, during, and after hospitalization for heart failure
(from Organized Program to Initiate Lifesaving Treatment in Hospitalized
Patients with Heart Failure). Am J Cardiol 2008, 102:1524–1529.
10. Peterson PN, Shetterly SM, Clarke CL, Bekelman DB, Chan PS, Allen LA,
Matlock DD, Magid DJ, Masoudi FA: Health literacy and outcomes among
patients with heart failure. JAMA 2011, 305:1695–1701.
11. Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, Shlipak MG:
Hemoglobin level, chronic kidney disease, and the risks of death and
hospitalization in adults with chronic heart failure: the Anemia in
Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR)
Study. Circulation 2006, 113:2713–2723.
12. Go AS, Yang J, Gurwitz JH, Hsu J, Lane K, Platt R: Comparative effectiveness
of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol)
on the risk of rehospitalization in adults with heart failure. Am J Cardiol
2007, 100:690–696.
13. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH: Statin therapy and risks for
death and hospitalization in chronic heart failure. JAMA 2006,
296(17):2105–2111.
14. Chaudhry SI, Wang Y, Concato J, Gill TM, Krumholz HM: Patterns of weight
change preceding hospitalization for heart failure. Circulation 2007,
116:1549–1554.
doi:10.1186/1471-2261-12-43
Cite this article as: Allen et al.: Patterns of beta-blocker intensification in
ambulatory heart failure patients and short-term association with
hospitalization. BMC Cardiovascular Disorders 2012 12:43.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
